An observational study in Moyamoya Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Beijing Tiantan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, none of them phase 3. Moyamoya Disease · Beijing Tiantan Hospital.
Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 9th registered.
62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.
Browse Moyamoya Disease studies →10 of the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–70
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Beijing Tiantan Hospital · Sites in China
Ages 18–60 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 330 is close to the median of 300 across 29 observational studies indexed under Moyamoya Disease.
Median enrollment 328 across the 3 interventional studies, 350 across the 11 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
2 of the studies in Moyamoya Disease by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05332756Beijing Tiantan HospitalLong-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA) | 2026-11-30 |
| NCT07517354Beijing Tiantan HospitalFamily-Based Moyamoya Susceptibility and Early Detection | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.
Patients diagnosed with MMD in Beijing Tiantan Hospital will be recruited. Eligibility will be determined through a checklist of inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Revascularization/Conservative management
Rate of participants experiencing cerebrovascular events (TIA, ischemic stroke, or hemorrhagic stroke)
The occurrence of cerebrovascular events, including TIA, ischemic stroke, or hemorrhagic stroke, will be assessed over an 18-month follow-up period.
Time frame: 18 months during follow-up
Changes in Neurological Function (mRS, NIHSS) at 12 and 18 Months After Treatment
The mRS and NIHSS will be used to assess changes in neurological function at 12 and 18 months after treatment.
Time frame: 12 and 18 months during follow-up
Changes in Cognitive Function (MoCA, MMSE) at 12 and 18 Months After Treatment
The MoCA and MMSE will be used to evaluate changes in cognitive function at 12 and 18 months after treatment.
Time frame: 12 and 18 months during follow-up
Structural Remodeling of the Internal Carotid Artery Terminal and Middle Cerebral Artery Wall at 12 and 18 Months After Treatment
High-resolution magnetic resonance vessel wall imaging will be used to evaluate structural remodeling changes in the internal carotid artery terminal and middle cerebral artery wall at 12 and 18 months after treatment.
Time frame: 12 and 18 months during follow-up
Changes in Cerebral Blood Perfusion at 12 and 18 Months After Treatment
ASL will be used to assess cerebral blood perfusion changes at 12 and 18 months after treatment.
Time frame: 12 and 18 months during follow-up
Rate of New Cerebral Infarcts at 12 and 18 Months After Treatment
The occurrence of new cerebral infarcts at 12 and 18 Months after treatment will be evaluated using MRI.
Time frame: 12 and 18 months during follow-up
Hemodynamic Changes at the Internal Carotid Artery Terminal at 12 and 18 Months After Treatment
4D-Flow MRI and hemodynamic analysis will be used to evaluate changes in hemodynamics at the internal carotid artery terminal at 12 and 18 months after treatment.
Time frame: 12 and 18 months during follow-up
Changes in Blood Lipid Levels at 12 and 18 Months After Treatment
Blood lipid levels will be measured and compared at 12 and 18 months after treatment.
Time frame: 12 and 18 months during follow-up
Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.